v3.26.1
Balance Sheet Details (Tables)
3 Months Ended
Mar. 31, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

 

 

 

March 31, 2026

 

 

December 31, 2025

 

Research and development costs

 

$

4,502

 

 

$

4,700

 

Compensation-related expenses

 

 

1,518

 

 

 

2,913

 

Other

 

 

755

 

 

 

422

 

Total accrued liabilities

 

$

6,775

 

 

$

8,035